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Amyloid β 1-42 induces hypometabolism in human stem
cell-derived neuron and astrocyte networks
Marta A Tarczyluk1, David A Nagel2, H Rhein Parri2, Erin HY Tse2, James E Brown2, Michael D Coleman2 and Eric J Hill2
Alzheimer’s disease (AD) is the most common form of dementia, affecting more than 35 million people worldwide. Brain
hypometabolism is a major feature of AD, appearing decades before cognitive decline and pathologic lesions. To date, the
majority of studies on hypometabolism in AD have used transgenic animal models or imaging studies of the human brain. As it is
almost impossible to validate these ﬁndings using human tissue, alternative models are required. In this study, we show that
human stem cell-derived neuron and astrocyte cultures treated with oligomers of amyloid beta 1-42 (Aβ1-42) also display a
clear hypometabolism, particularly with regard to utilization of substrates such as glucose, pyruvate, lactate, and glutamate.
In addition, a signiﬁcant increase in the glycogen content of cells was also observed. These changes were accompanied by changes
in NAD+/NADH, ATP, and glutathione levels, suggesting a disruption in the energy-redox axis within these cultures. The high energy
demands associated with neuronal functions such as memory formation and protection from oxidative stress put these cells at
particular risk from Aβ-induced hypometabolism. Further research using this model may elucidate the mechanisms associated with
Aβ-induced hypometabolism.
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INTRODUCTION
It is now widely accepted that Alzheimer’s disease (AD) is
accompanied by hypometabolism, of differing severity in different
regions of the brain. Crucially, signs of hypometbolism such as a
reduction in central nervous system glucose utilization as well as
mitochondrial function, begin decades before any symptoms or
histopathologic changes appear, making such events useful
biomarkers of AD risk.1 In addition, reductions in key mitochon-
drial enzyme complex activities such as the α-ketoglutarate
dehydrogenase complex have been observed.2
One obvious explanation for the observed reduction in glucose
utilization could be neuronal loss, which is observed in AD
patients. However, many studies have shown a reduction in the
cerebral metabolic rate of glucose before the onset of the disease
and subsequent cell loss. This has been seen in individuals at risk
of developing AD such as APOE4 carriers, those carrying
autosomal dominant mutations linked with familial AD or patients
with mild cognitive impairment.3 As hypometabolism is the
earliest signiﬁcant event linked with AD, it suggests that changes
in energy metabolism precede neuronal loss and may actually
contribute to the development and progression of the disease.
To investigate these changes, a number of in vivo studies have
attempted to model changes in cerebral glucose utilization in
transgenic mice. However, conﬂicting results have been reported
and were dependent on the model used. Studies using models
that overexpress the Swedish and Indiana mutations of human
amyloid precursor protein4 as well as the 3xTG model of AD, which
overexpresses human amyloid precursor protein, PS1, and tau
mutations5 have showed reductions in cerebral glucose uptake.
While studies using the Tg2576 mouse model that over expresses
the Swedish mutation of amyloid precursor protein,6 as well as a
model that overexpresses the Swedish and London mutations of
amyloid precursor protein, along with PS17 have all displayed an
increase in brain glucose uptake.
Furthermore, reductions in glucose uptake in response to
Aβ have also been reported in vitro using primary rat hippocampal
neurons,8,9 while in contrast, an increase in glucose uptake has
been reported in primary mouse astrocytes.10
Difﬁculties in obtaining viable human tissue from living patients
have made it almost impossible to validate these ﬁndings in
human neurons. It is clearly important to be able to model glucose
metabolic changes in tissues and experimental models that are
directly relevant to the disease. While rodent and human brain
share a number of common features, rodent models do not
naturally develop AD; indeed, it is important note the differences
between the human and rodent central nervous system. Human
cortical astrocytes have been shown to be both larger and
structurally more complex and diverse than those of rodents.11
These ﬁndings highlight fundamental differences between species
used to study human diseases and show the importance of
developing functional human models that can be used in
comparative studies.
In this way, it may be possible not only to replicate the ﬁndings
observed in human patients but also to test novel hypotheses that
may predict changes in human brain tissue. As such, human stem
cell-derived models may provide the most simplistic and relevant
platforms to study cell–cell interaction in AD. To this end, we have
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used human NT2.D1 stem cell-derived neuron and astrocyte co-
cultures to determine the effects of exposure to oligomeric Aβ1-42
on cellular metabolism and oxidative stress in comparison with
primary rat hippocampal cultures.
The NT2.D1 embryocarcinoma cell line is well characterized and
generates neuronal (NT2.N) cells containing heterogeneous
subpopulations of dopaminergic, cholinergic, GABAergic, and
glutamatergic neurons12–15 as well as astrocytic (NT2.A) cells.16,17
These cells have been shown to generate action potentials on
depolarization18 and form functional spontaneously active neuro-
nal networks.19 We have shown recently that these cells show
metabolic coupling and can link neuronal activity to changes in
astrocytic metabolism.20 Critically, increasing numbers of studies
have highlighted the important role of astrocytes in AD.21 Indeed,
astrocytes in the healthy brain enhance neuronal survival, axonal
growth, synaptogenesis, as well as neurovascular and neurometa-
bolic coupling; hence, their inclusion confers structural and
functional relevance in any model of brain function.
Crucially, recent studies have also showed the role of human
astrocytes early in AD22 and have reported metabolic changes
after treatment of primary mouse astrocyte cultures with Aβ oligo-
mers10 thus supporting the inclusion of astrocytes into in vitro
models of AD.
As changes in brain metabolism occur decades before any other
symptoms, the development of relevant human models of the
earliest signiﬁcant metabolic foundations of the disease may
provide important future insights into disease process milestones,
that may one day be therapeutic targets. Therefore, this study
focused on using cocultures of human NT2-derived neurons and




Hexaﬂuoroisopropanol (HFIP) treated Aβ1-42 (Anaspec, Freemont, CA,
USA) was resuspended in 200mmol/L HEPES, pH 8.5 to a concentration of
100 μmol/L. Treatment with HFIP has previously been shown to dissolve
higher aggregates, eliminating the ‘nucleating seeds’ and removing any
secondary or tertiary structures.23 The aliquots were stored at − 80°C
and used at working concentrations of 20, 2, and 0.2 μmol/L. These
concentrations were selected based on the previous research demonstrat-
ing the toxicity of Amyloid oligomers in primary cultures.23,24 In addition,
these concentrations are within the micromolar concentration range of
soluble and insoluble Aβ1-42 levels reported in AD patient brain tissue.25
Cell Culture
Human teratocarcinoma NT2.D1 cells used in this study were kindly
donated by Professor Andrews (University of Shefﬁeld, UK). The cells were
cultured in DMEM (Dulbecco's Modiﬁed Eagle Medium) high glucose,
containing, Glutamax, (Life Technologies, Paisley, UK), 10% heat inactivated
fetal bovine serum (Life Technologies), 100 units/mL penicillin, and 100 μg/mL
streptomycin. NT2.D1 cells were differentiated according to the previously
published methods.26 Brieﬂy, NT2.D1 cells were differentiated using
DMEM Glutamax high glucose medium with pyruvate, supplemented with
10% (v/v) fetal bovine serum, 100 units/mL penicillin, 100 μg/mL
streptomycin (pen/strep), and 1× 10− 5 M all-trans retinoic acid (RA)
(Sigma-Aldrich, Dorset, UK) for 4 weeks. Differentiated cells were seeded at
a lower density, then dislodged and re-seeded onto CellBIND 12-well
plates (Corning, New York, USA) at 1.25 × 106 cells/well and treated with
medium containing antiproliferative agents (MI) for 28 days; 0.1 μmol/L
cytosine arabinoside (for the ﬁrst 7 days only), 3 μmol/L ﬂuorodeoxyur-
idine, and 5 μmol/L uridine. Pure astrocytic cultures were produced as
previously described.26 Brieﬂy, NT2.N/A cells were dissociated into a single-
cell suspension using Accutase (PAA Laboratories, Yeovil, UK) and
subsequently seeded onto fresh CellBIND 12-well plates in MI-free
medium. After incubation for 2 hours, the plates were shaken brieﬂy using
a plate shaker (400 r.p.m.) to dissociate loose NT2.N cells from the more
adherent NT2.A cells leaving an astrocytic mono-layer after rinsing. All cells
were maintained by incubation at 37°C in a humidiﬁed atmosphere of 5%
CO2. Unless otherwise stated, all experiments were performed at 37°C in a
humidiﬁed atmosphere of 5% CO2. The proportion of cell types produced
by this method in this study were in agreement with previously published
values (33 ± 4% neurons and 63± 4% astrocytes).26
Primary Cortical Cultures
All procedures were approved by Aston University Bioethics committee, and
performed in accordance with the UK Animals (Scientiﬁc Procedures) Act
1986 and associated procedures. Cortical cultures were prepared from 2- to
3-day-old male Wistar rats. Animals were anesthetized with isoﬂurane and
euthanized by cervical dislocation. After removal, the brain was
placed in ice-cold Gey’s salt solution (Sigma-Aldrich) containing 20 μg/mL
gentamycin (Life Technologies). The cortex was dissected and placed in ice-
cold Gey’s salt solution containing 20 μg/mL gentamycin. The tissue was then
minced using a scalpel and placed in Ca2+-free and Mg2+-free Hanks’
buffered saline solution (Life Technologies), containing 0.1% trypsin (Life
Technologies) for 30minutes at 37°C. The trypsin was inactivated by adding
Neurobasal medium (Life Technologies) containing B27 (Life Technologies),
100 units/mL penicillin and 100 μg/mL streptomycin and 10% horse serum
(Life Technologies). Cells were then centrifuged at 258 g for 5minutes and
then medium was replaced with 5mL of fresh Neurobasal medium. Cells
were dissociated by trituration with a glass Pasteur pipette with a ﬂame-
rounded tip and passed through 70 μm ﬁlter (BD Biosciences, Oxford, UK).
Cells were counted using a hemocytometer and plated onto poly-D-lysine
coated 12-well plates at a ﬁnal concentration of 5×105 cells/mL. Cells were
maintained at 37°C and 5% CO2 and fed twice a week, cells were used after
5 days. Plates for primary cortical cultures were coated with poly-D-lysine
(Sigma-Aldrich) at a concentration of 50 μg/mL. Brieﬂy, poly-D-lysine was
resuspended in sterile H2O and ﬁltered through 0.22 μm ﬁlter, the wells were
coated with 2mL of the solution and incubated at 37°C overnight. The poly-
D-lysine was aspirated and plates were rinsed with sterile H2O and dried.
Cell Viability
The viability of the cultures after treatment with Aβ1-42 was determined
using the Cell-titre Blue assay (Promega, Southampton, UK). After
experimental treatment, medium was removed from the wells of the 12-
well cell-culture plate. Subsequently, the plate was washed with 500 μL
phenol red-free DMEM media (Life Technologies), supplemented with 10%
heat inactivated fetal bovine serum (NT2.N/A, NT2.A) or 10% horse serum
(primary cortical cultures), 100 units/mL penicillin and 100 μg/mL strepto-
mycin and 2mmol/L L-glutamine. In all, 1 mL of Cell-titre blue reagent was
mixed with 10mL of the DMEM. In all, 500 μL of this solution was added to
each well of the plate. The plate was incubated for 3 hours at 37°C.
After incubation, medium was transferred to a 96-well plate and the
absorbance was measured at 590 nm using a Thermo multiscan EX 96-well
plate reader (Thermoﬁsher, Loughborough, UK).
Determination of Carbohydrate Levels
The levels of glycogen in biological samples were determined using the
method described by Nahorski and Rogers.27 Lactate was measured using
the Fluorescent Lactate Assay Kit (Abcam, Cambridge, UK) according to the
manufacturer’s instructions. Pyruvate was measured using the Pyruvate
assay kit (Abcam) according to the manufacturer’s instructions. Glucose
levels were measured using Glucose (HK) Assay Kit (Sigma-Aldrich)
according to the manufacturer’s instructions.
NAD/NADH
NAD+/NADH ratio was measured using the NAD/NADH assay kit (Abcam)
according to the manufacturer’s instructions.
ATP
ATP levels were measured using the CellTiter-Glo kit (Promega) according
to the manufacturer’s instructions.
Determination of Glutamate Levels
Glutamate levels were measured using Amplex Red Glutamic Acid/
Glutamate Oxidase Assay kit (Life Technologies).
Glutathione (GSH)/Glutathione Disulﬁde (GSSG) Assay
Glutathione/GSSG was measured as previously described.28
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Statistics
Results were expressed as the mean of three samples ± standard error of
the mean (s.e.m.). Comparisons between treatments were performed using
analysis of variance (ANOVA) followed by Dunnett’s or Tukey’s post test
or where appropriate Student’s T-test using GraphPad Prism Software
(GraphPad Prism software, La Jolla, CA, USA). Differences were considered
as signiﬁcant for P values o0.05.
RESULTS
Characterization of Cells
After differentiation, the cultures began to display distinct
neuronal and astrocytic morphology. Neurons extended axons
and dendrites, and astrocytes with projections appeared in close
proximity to aggregations of neuronal perikarya and neurites
throughout the culture. Under the microscope astrocytes were
identiﬁed by their ﬂat phase dark appearance, while neurons were
typically phase bright and often seen on top of the astrocytic
monolayer. Identiﬁcation was conﬁrmed using immunohisto-
chemistry for the speciﬁc markers GFAP and β-tubulin (Figures
1A and 1B).
Primary mixed glial and neuronal cultures were prepared from
cortices of Wistar rat pups and maintained in Neurobasal media.
These cultures produced a mixed culture of astrocytes and
neurons (Figures 1C and 1D).
Amyloid Aggregation
To assess the composition of each preparation, freshly prepared
samples of Aβ(1-42) at a concentration of 20 μmol/L were
separated using SDS and Native polyacrylamide gel electro-
phoresis and visualized using western blotting (Figure 2A).
Aβ(1-42) prepared in 100mmol/L HEPES at pH 8.5 showed a large
proportion of monomers at around ~ 4 kDa and high n-oligomers
at the top of the gel (~130 to 250 kDa) (Figure 2A).
The Effects of Amyloid on Cell Viability
To determine the temporal and concentration-dependent effects
of Aβ on NT2.N/A cocultures, NT2.A cultures, and mixed rat glial
and neuronal cultures, cells were treated with different concen-
trations of Aβ1-42 oligomers (0.2, 2, and 20 μmol/L) for 6, 24, 48,
72, and 96 hours. After treatment, the viability of the cells was
measured indirectly using Cell-titre blue assay (Promega).
In cocultures the only signiﬁcant change was seen at the
highest concentration of Aβ1-42 when compared with the un-
treated control (Figure 2B). Application of 20 μmol/L Aβ caused an
Figure 1. Immunoﬂuorescent images of NT2/D1-derived neurons and astrocytes (A and B) and primary cortical mixed neuronal and glial
cultures (C and D). Images showing (A) β-tubulin-positive neurons (green) and (B) GFAP- (red) positive astrocytes. Scale bar 23 μm. Images
showing (C) β-tubulin-positive neurons (green) and (D) GFAP- (red) positive astrocytes. Scale bar 24.9 μm.
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increase in reduction of resazurin at 6 hours (112 ± 4.2%, Po0.05)
and a decrease at 48 hours (89 ± 4.3%, Po0.05) compared with
control. In the pure astrocytic cultures, there was a signiﬁcant
increase in the reduction of resazurin in the cells treated with
0.2 μmol/L Aβ for 72 hours (106 ± 2.1%, Po0.05) (Figure 2C).
Similarly the primary cortical cultures did not show any signiﬁcant
cell death over time (Figure 2D). After 24 hours treatment with 20
and 0.2 μmol/L the cultures showed an increase in the reduction
of resazurin (20 μmol/L: 107 ± 1.7, Po0.05; 0.2 μmol/L: 108 ± 1.3%,
Po0.05). The same increase in the reduction of resazurin was
seen after 72 hours treatment with the highest concentration of
Aβ (106 ± 0.99%, Po0.05).
Glucose Uptake Is Decreased After Treatment with Amyloid Beta
To determine the effect of amyloid on glucose uptake, the glucose
concentration of media from Aβ-treated cells was measured using
the Glucose (Hexokinase) Assay Kit (Sigma-Aldrich). NT2.N/A, NT2.A
and primary cortical cultures all showed a signiﬁcant decrease in
glucose uptake after treatment with 2 and 0.2 μmol/L Aβ at all
time points investigated. Glucose levels in the medium from
cocultures were signiﬁcantly increased (Po0.001) at all time
points (Figure 3A). Similar increases in the glucose content of
culture media were also seen in primary cortical cultures
(Po0.001) at all time points with the exception of 2 μmol/L Aβ
treatment at 6 hours (Figure 3C). Astrocytic cultures also showed
a decrease in glucose uptake, though to a lesser extent
than neuronal and astrocytic cocultures (Figure 3B). At 24 hours,
the glucose levels in the media were signiﬁcantly increased after
the treatment with Aβ (control: 10.2 ± 0.29mmol/L; 2 μmol/L:
12.3 ± 0.09mmol/L, Po0.001; 0.2 μmol/L: 12.5 ± 0.25 mmol/L,
Po0.001). The decrease in glucose uptake became less signiﬁcant
over time in astrocytes. At 72 hours, the increase in glucose
content in culture media is at Po0.05 for both concentrations and
at 96 hours only 0.2 μmol/L Aβ treatment had any substantial
impact (Po0.05).
The glucose uptake over time differed between the cultures. In
all cases the starting concentration of glucose in the medium was
25mmol/L. The NT2.N/A cultures used up over 50% of the
available glucose in the ﬁrst 6 hours (control: 10.1 ± 0.19mmol/L).
Pure astrocytic cultures took up less glucose than cocultures
(control: 11.5 ± 0.36 mmol/L; Po0.05) while uptake in primary
cultures was even slower (control: 16.4 ± 0.31 mmol/L; Po0.0001).
Primary cortical cultures were more sensitive to Aβ treatment
and glucose uptake was blocked to a greater extent than in NT2.
N/A or NT2.A cultures. After 96 hours, primary cortical cultures
treated with 0.2 μmol/L Aβ depleted 57.7 ± 2%, (Po0.001) of the
glucose from the media compared with the control (98.6 ± 0.25%)
while NT2.N/A used up 92.8 ± 0.28%, compared with the control
(96.1 ± 0.05%; Po0.001 ) and NT2.A 87.5 ± 0.34%, compared with
the control (89.1 ± 0.17%; Po0.05).
Intracellular Glucose and Glucose-6-Phosphate Is Increased After
Treatment with Amyloid Beta
Intracellular glucose and glucose-6-phosphate levels were mea-
sured after the treatment with Aβ. As in previous experiments the
changes in glucose levels were restricted to the two lower
concentrations of Aβ, 2 and 0.2 μmol/L. The NT2.N/A cocultures
showed an accumulation of glucose and glucose-6-phosphate at
all time points (Figure 3G). The increase in glucose content was
most signiﬁcant at 6 hours (control: 116 ± 5.61 nmol/mg protein;
0.2 μmol/L: 172 ± 9.06 nmol/mg protein; Po0.01) and 24 hours
time point (control: 84.8 ± 3.9 nmol/mg protein; 0.2 μmol/L:
Figure 2. (A) Representative western blot analysis of Amyloid Beta 1-42 (Aβ(1-42)) dissolved in HEPES and separated using (I) denaturing
and (II) native conditions. Viability results after treatment with 20, 2, and 0.2 μmol/L Aβ. (B) NT2.N/A, (C) NT2.A, and (D) primary
cortical cultures. Viability was measured after 6, 24, 48, 72, and 96 hours. Results are expressed as percentage of nontreated
control± s.e.m., n= 3. Po0.05 (*). Comparisons between treatments were performed using analysis of variance (ANOVA) followed by
Dunnet’s post test.
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139± 14.1 nmol/mg protein; Po0.01). A more signiﬁcant accu-
mulation of glucose and glucose-6-phosphate was observed in
astrocytes than in cocultures, with 6 hours (control: 110 ± 8.4
nmol/mg protein; 0.2 μmol/L: 214 ± 14 nmol/mg protein,
Po0.001) and 24 hours time points (control: 143 ± 8.6 nmol/mg
protein; 0.2 μmol/L: 211 ± 6.3 nmol/mg protein, Po0.001) showing
the largest increase (Figure 3H). Similarly primary cortical cultures
also showed a very signiﬁcant (Po0.001) accumulation at all time
points after treatment with Aβ (Figure 3I).
Intracellular Glycogen Is Increased after Treatment with Amyloid
Beta
The levels of glycogen within the control cultures were stable
throughout the incubation period (Figure 3D). After the treatment
of the cultures with Aβ, glycogen levels inside the cells were
measured at 6, 24, 48, 72, and 96 hours. NT2.N/A cocultures
showed an initial decrease in glycogen levels at 6 hours compared
with control (0.2 μmol/L: 96.1 ± 0.47%, Po0.001; 2 μmol/L:
96.6 ± 0.15%, Po0.001) (Figure 3D). Glycogen levels increased to
control levels at 24 hours, with signiﬁcant (Po0.001) increases at
72 hours to 129 ± 5.57% when treated with 2 μmol/L Aβ and to
123± 3.94% with 0.2 μmol/L Aβ. At 96 hours, the differences were
less apparent with only 0.2 μmol/L Aβ having a signiﬁcant effect
(113 ± 4.32%, Po0.05) (Figure 3D). Primary cortical cultures
showed a similar pattern, with glycogen levels increasing at 48
hours. However, the increase in glycogen was more signiﬁcant
and at 96 hours levels of glycogen reached 277 ± 16.5% (Po0.001)
after treatment with 2 μmol/L Aβ and 259 ± 19.9% (Po0.001)
when treated with 0.2 μmol/L Aβ (Figure 3F). Additionally, from
48 hours there was a decrease in glycogen levels in cells treated
with 20 μmol/L Aβ which was signiﬁcant at 48 hours (Po0.001)
and 72 hours (Po0.001).
Pure astrocytes also showed an increase in glycogen levels from
6 hours (2 μmol/L: 130 ± 7.1%, Po0.01) (Figure 3E). Increases were
observed at all time points, but were only signiﬁcant at 24 and
96 hours.
Lactate Levels in the Cell Conditioned Media Are Signiﬁcantly
Decreased After Treatment with Amyloid Beta
Lactate levels in the cell conditioned media after treatment
with Aβ were found to be signiﬁcantly decreased in NT2.N/A
Figure 3. Glucose levels in the media and glycogen and glucose/glucose phosphate levels inside the cells after treatment of cultures with
20 , 2, and 0.2 μmol/L amyloid beta (Aβ). Metabolite levels were measured after 6, 24, 48, 72, and 96 hours. Glucose levels in the media. (A) NT2.
N/A, (B) NT2.A, and (C) primary cortical cultures. Results are expressed as mmol/L± s.e.m., n= 3. Glycogen levels inside the cells (D) NT2.N/A,
(E) NT2.A, and (F) primary cortical cultures. Glucose and Glucose-6-phosphate levels inside the cells (G) NT2.N/A, (H) NT2.A, and (I) primary
cortical cultures. Results are expressed as nmol/mg protein± s.e.m., n= 3 Po0.05 (*), Po0.01 (**), Po0.001 (***). Comparisons between
treatments were performed using analysis of variance (ANOVA) followed by Dunnet’s post test.
Aβ1-42 induced hypometabolism
MA Tarczyluk et al
1352
Journal of Cerebral Blood Flow & Metabolism (2015), 1348 – 1357 © 2015 ISCBFM
cocultures. At 6 hours, there was no signiﬁcant change in lactate
levels.
However, after 24 hours the levels were decreased after
treatment with both 0.2 and 2 μmol/L Aβ (control: 13.6 ± 0.3
mmol/L; 2 μmol/L: 10.6 ± 0.1 mmol/L, Po0.01; 0.2 μmol/L: 9.5 ± 0.6
mmol/L, Po0.001) (Figure 4A). The decrease was also seen at 48
and 72 hours; however, at 96 hours, levels of lactate were similar
to control levels (control: 19.95 ± 0.18 mmol/L; 2 μmol/L:
19.9 ± 0.78mmol/L; 0.2 μmol/L: 21.3 ± 0.33 mmol/L). Pure astro-
cytes did not show any change after the treatment with Aβ.
Interestingly, levels of lactate in pure astrocyte cultures were much
lower than in cocultures (Figure 4B). In primary cortical cultures,
the decrease in lactate was very signiﬁcant and was seen from
6 hours (control: 5.23 ± 0.41 mmol/L; 2 μmol/L: 3.75 ± 0.10 mmol/L,
Po0.01; 0.2 μmol/L: 3.8 ± 0.1 mmol/L, Po0.01) through to 96
hours (control: 19.4 ± 0.97 mmol/L; 2 μmol/L: 13.3 ± 0.9 mmol/L,
Po0.001; 0.2 μmol/L: 10.2 ± 1.1 mmol/L, Po0.001) (Figure 4C).
Lactate was found to accumulate over time in all cultures. In
NT2.N/A cultures and primary cultures, the lactate levels were
much higher than in pure astrocytes. Additionally, in NT2.N/A
cocultures the accumulation of lactate was slower than in primary
cultures. NT2.N/A lactate reached 19.95 ± 0.18mmol/L levels at
96 hours while primary cultures attained 20.6 ± 0.8 mmol/L levels
at 48 hours after which time the levels remained stable.
Pyruvate Levels in the Cell Conditioned Media Are Signiﬁcantly
Increased After Treatment with Amyloid Beta
The levels of pyruvate in the cell culture media were measured
after treatment with Aβ. The initial pyruvate concentration in NT2.
N/A and NT2.A medium was 1mmol/L while in primary cortical
cultures the initial pyruvate concentration was 200 μmol/L.
All cultures showed a signiﬁcant reduction in pyruvate levels in
cell culture media over time regardless of treatment. In NT2.N/A
cultures treated with both 0.2 and 2 μmol/L Aβ, the pyruvate
content in the cell culture media was higher than the control. The
most signiﬁcant increase was seen at 24 hours (control: 398 ± 7.7
μmol/L; 2 μmol/L: 447 ± 15.9 μmol/L, Po0.05; 0.2 μmol/L: 461 ± 8.3
μmol/L, Po0.01) and 48 hours (control: 327 ± 8.7 μmol/L; 2 μmol/L:
364 ± 7.6 μmol/L, Po0.05; 0.2 μmol/L: 380 ± 6.97 μmol/L, Po0.01)
(Figure 4D). However, at 96 hours the level of pyruvate decreased
Figure 4. Lactate, pyruvate, and glutamate levels in the media after treatment of cultures with 20, 2, and 0.2 μmol/L Amyloid beta (Aβ).
Metabolite levels were measured after 6, 24, 48, 72, and 96 hours. Lactate levels in the media (A) NT2.N/A, (B) NT2.A, and (C) primary cortical
cultures. Results are expressed as mmol/L± s.e.m., n= 3. Pyruvate levels in the media (D) NT2.N/A, (E) NT2.A, and (F) primary cortical cultures.
Results are expressed as mmol/L± s.e.m., n= 3. Glutamate levels in the media (G) NT2.N/A, (H) NT2.A, and (I) primary cortical cultures. Results
are expressed as μmol/L± s.e.m., n= 3. Po0.05 (*), Po0.01 (**), Po0.001 (***). Comparisons between treatments were performed using
analysis of variance (ANOVA) followed by Dunnet’s post test.
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signiﬁcantly in comparison with control (Figure 4D). In pure
astrocytes, there was no change in the concentration of pyruvate
after the treatment with Aβ (Figure 4E). Primary cortical cultures
showed a similar pattern to NT2.N/A cocultures, with an increase
in the concentration of pyruvate becoming more signiﬁcant
after 6 hours (Figure 4F). Conversely to NT2.N/A cocultures
(Figure 4F) there was no decrease at 96 hours in primary cortical
culture (control: 4.19 ± 0.44 μmol/L; 2 μmol/L: 19.6 ± 0.89 μmol/L,
Po0.001; 0.2 μmol/L: 21.0 ± 0.91 μmol/L, Po0.001).
Glutamate Levels in the Cell Conditioned Media Are Signiﬁcantly
Decreased after Treatment with Amyloid Beta
Treatment with Aβ was also found to have an effect on glutamate
levels in the media. In NT2.N/A cocultures, there was a signiﬁcant
decrease in glutamate levels from 24 hours with the largest
decrease at 72 hours and 96 hours (control: 22.3 ± 1.19 μmol/L;
2 μmol/L: 13.3 ± 0.41 μmol/L, Po0.001; 0.2 μmol/L: 13.05 ± 1.52
μmol/L, Po0.001) (Figure 4G). This decrease became more
signiﬁcant with time, as the control and 20 μmol/L Aβ-treated
cells accumulated more glutamate in the media. In pure astro-
cytes, the decrease was also present but to a lesser extent
(Figure 4H). Overall, the levels of glutamate in the media samples
were markedly lower in pure astrocytic cultures than cocultures of
neurons and astrocytes. Primary cortical cultures also showed a
signiﬁcant decrease in glutamate levels after treatment with 2 and
0.2 μmol/L Aβ. The decrease was signiﬁcant from 24 hours and
most signiﬁcant at 96 hours (control: 9.08 ± 0.34 μmol/L; 2 μmol/L:
5.51 ± 0.37 μmol/L, Po0.001; 0.2 μmol/L: 5.35 ± 0.43 μmol/L,
Po0.001) (Figure 4I).
The Cellular GSH/GSSG Ratio Is Signiﬁcantly Decreased after
Treatment with Amyloid Beta
The total GSH and GSSG levels of cultures varied dependent on
the length of incubation and treatment (Supplementary material).
NT2.N/A cocultures treated with all concentrations of Aβ showed a
signiﬁcant decrease in the GSH/GSSG ratio at 6 and 24 hours
(Figure 5A). Pure astrocytes also showed a decrease in GSH/GSSG
ratio from the 6-hour time point (Figure 5B). This decrease was
signiﬁcant up to 48 hours time point. After 72 hours, the GSH/GSSG
ratio increased to control ratio (control: 18.4 ± 1.67; 20 μmol/L:
18.7 ± 1.8; 2 μmol/L: 23.1 ± 1.8; 0.2 μmol/L: 21.8 ± 1.22). At 96 hours,
there was a further increase in the ratio (Figure 5B), which was
signiﬁcant at all three concentrations (Po0.05). In NT2.N/A after
treatment with Aβ GSSG levels varied from 2.74% to 5.71% of the
total GSH-GSSG levels, compared with the controls 1.75% to
2.89%. In NT2.A after treatments GSSG levels were higher varying
from 3.67% to 18.2%, with controls 4.76% to 10.7%.
The Cellular NAD+/NADH Ratios and ATP Levels Are Signiﬁcantly
Decreased after Treatment with Amyloid Beta
NAD+/NADH ratios and ATP levels were measured in NT2.N/A
cocultures after treatment with 2 μmol/L Aβ. The NAD+/NADH
ratio increased at 24 hours and was followed by a steady decrease
at 48, 72, and 96 hours (Figure 6A). Both Aβ treated and control
cells followed this trend. There was an initial increase in NAD+/
NADH ratio after the treatment with Aβ at 24 hours (control:
0.66 ± 0.06; 2 μmol/L: 0.91 ± 0.02, Po0.05). However, after this
time point the ratio was much lower after the Aβ treatment
and became signiﬁcantly lower at 96 hours (control: 0.52 ± 0.03;
2 μmol/L: 0.18 ± 0.01, Po0.001). At 96 hours NAD+ levels in
control were 820± 17.5 pmol/mg of protein, while after treatment
with 2 μmol/L, Aβ levels decreased to 348± 20.2 pmol/mg of
protein. ATP levels after treatment with 2 μmol/L Aβ decreased
from 6 hours, becoming signiﬁcant at 24 hours (Figure 6B). ATP
levels reached their lowest levels at 72 and 96 hours (control:
8.34 ± 0.86 nmol/mg protein; 2 μmol/L: 3.29 ± 0.20 nmol/mg pro-
tein, Po0.01).
DISCUSSION
Difﬁculties in studying the cellular mechanisms of AD in living
patients combined with shortcomings in the relevance of animal
models have conﬁned much AD research to the end-stage
pathologies (Aβ plaques and Tau tangles). Clinical imaging
approaches in mild cognitive impairment or early-stage AD have
provided intriguing insights into the early stages of AD but have
been unable to explore these changes at the cellular level.
In this study, we provide the ﬁrst description of the impact of Aβ
on glucose homeostasis in neurons and astrocytes derived from
human stem cells. Furthermore, we show changes in the
utilization of metabolites such as lactate, pyruvate, and glutamate.
In addition, we show an increase in the storage of glycogen as
well as changes in the NAD/NADH ratio as well as ATP levels
within cells. Since hypometabolism is a key feature of AD, this
model may provide a complex functional in vitro system for
studying early changes in disease pathology.
Human stem cell-derived cocultures of neurons and astrocytes
successfully modelled the earliest metabolic changes induced by
Aβ. In addition, results obtained from these cells were compared
with a well-characterized primary rat cortical tissue culture
preparation. As the NT2 line is a form of human stem cell, our
protocol concept in this report should inform the design of future
studies using patient-derived induced pluripotent stem cells. NT2
cultures treated acutely with exogenous Aβ in this study show
‘metabolic toxicity’ over a period of hours/days. As such changes
in metabolic homeostasis are observed before the development of
symptoms in patients, it would be of great interest to model the
Figure 5. GSH/GSSG ratio inside the cells after treatment with 20, 2,
and 0.2 μmol/L Amyloid beta (Aβ). (A) NT2.N/A and (B) NT2.A. GSH
and GSSG were measured after 6, 24, 48, 72, and 96 hours and were
normalized to protein concentration. Results are expressed as
ratio± s.e.m., n= 3. Po0.05 (*), Po0.01 (**), Po0.001 (***).
Comparisons between treatments were performed using analysis
of variance (ANOVA) followed by Dunnet’s post test.
Aβ1-42 induced hypometabolism
MA Tarczyluk et al
1354
Journal of Cerebral Blood Flow & Metabolism (2015), 1348 – 1357 © 2015 ISCBFM
long-term effects of Aβ on cellular viability in culture. However,
caution should be taken with the interpretation of this response
when modelling a disease that may take years/decades to develop
in vivo. In addition, the concentration of glucose in the media used
(25 mmol/L) may impact upon the metabolism of cells and
therefore their survival after Aβ treatment. Future studies will
determine the effect of low glucose concentrations on cell
survival.
After exposure to Aβ, the cultures showed a decrease in the
uptake and/or utilization of glucose. A decrease in glucose uptake
upon treatment with 2 and 0.2 μmol/L Aβ1-42 could be explained
by the accumulation of glucose and glucose-6-phosphate that was
observed intracellularly. This could lead to a reduction in the ﬂow
of glucose through the hexokinase pathway due to allosteric
feedback inhibition of hexokinase. Indeed amyloid itself may
decrease hexokinase activity via interference with hexokinase
activity and subcellular localization.29
The increase in glycogen levels after the treatment with 2 and
0.2 μmol/L Aβ1-42 could also be explained by accumulation of
glucose-6-phosphate, which instead of passing through glycolysis,
is directed through glycogen synthesis pathways. However, very
little is understood about the storage and metabolism of glycogen
during AD and further research is required to understand the
impacts of these changes on cellular processes.
In this report, glutamate production in both rat cortical and
human NT2.N/A cocultures was shown to be affected after
treatment with Aβ1-42. In addition, overall glutamate levels in
pure NT2-A astrocytic cultures were lower compared with those of
cocultures. This is not unexpected as the majority of glutamate is
produced by neurons, while astrocytes take up the glutamate
released by neurons and convert it to glutamine. Previous
studies of AD patient brains have showed a decrease in glutamine
synthase, as well as a marked decrease in phosphate-activated
glutaminase levels and α-ketoglutarate dehydrogenase complex.2,30–33
Such changes could conceivably lead to disturbances in glutamate
production and recycling in vivo. Indeed, studies using magnetic
resonance spectroscopy have showed that patients with AD have
lower levels of brain glutamate compared to controls with mild
cognitive impairmen patients demonstrating intermediate levels.34
After exposure to Aβ1-42, lactate levels were signiﬁcantly
decreased in both coculture systems. Interestingly, this effect is
not seen in pure astrocytes. The results shown herein strongly
suggest that Aβ1-42 leads to inhibition of the glycolytic pathway,
which results in the accumulation of glucose/glucose-6-phos-
phate, decreased uptake of glucose and therefore possibly lactate
production. The pathway involved in the production of lactate by
astrocytes in the brain is unclear. According to the Astrocyte
Neuron Lactate Shuttle hypothesis, lactate production in astro-
cytes is triggered in response to glutamate uptake.35 However,
Dienel and McKenna36 have suggested various other metabolic
pathways including glutamate oxidation and glycolysis with
lactate release that can contribute to the energy demands of
excitatory neurotransmission.
Uptake of pyruvate, which has been shown to be an important
energy source in isolated mitochondria from brain,37 was also
decreased after treatment with low levels of Aβ1-42 in NT2.N/A
cocultures and primary cortical cultures, further limiting avail-
ability of substrates for the TCA cycle. However, the relevance of
this ﬁnding to the whole brain is unclear with brain cells relying
almost exclusively on glucose to meet its energy demands.
Interestingly, higher concentrations of amyloid (20 μmol/L) did
not have the same effects on metabolism as lower concentrations
(2 and 0.2 μmol/L). The kinetics of protoﬁbril formation are greatly
dependent on ambient conditions such as temperature, buffer
composition, and peptide concentration.38 It is possible that
higher concentrations of amyloid used in this study may
aggregate faster and thus produce amyloid species with altered
toxic effects. As such, it is conceivable that such species may not
initiate the metabolic effects observed in these cultures after
treatment with lower concentrations.
As the treatment of cells with Aβ1-42 leads to a decrease in the
substrates available for entry into the TCA cycle, changes in the
ratio of NAD+/NADH were investigated. Cocultures showed an
initial increase in NAD+/NADH ratio in both control and Aβ-treated
cells and this was followed by a signiﬁcant decrease, particularly in
Aβ-treated cells. Increases in the NAD+/NADH ratio seen in the
control cultures is possibly a result of increased glycolysis and
subsequent production of lactate after the application of fresh
media.
During glycolysis NAD+ is reduced to NADH. Normally
regeneration of NAD+ takes place in mitochondria via the
malate/aspartate shuttle. However, it has been shown that
astrocytes express low levels of a key component of this shuttle
and may instead use the conversion of pyruvate to lactate by
lactate dehydrogenase to regenerate NAD.39,40
A decrease in the availability of substrates (glucose, pyruvate)
and an increase in the requirement for NAD+ can lead to NAD+
depletion. In addition, decrease in NAD+ stores leads to a heavy
demand on ATP stores for synthesis of new NAD+,41 which in turn
could provoke an energy crisis in the cell.42 In this study,
treatment of NT2.D1-derived cocultures with 0.2 μmol/L Aβ1-42
caused a signiﬁcant decrease in ATP levels from 6 hours onwards
in comparison with the control, further highlighting the negative
impact of the peptide on cellular energy metabolism.
Dringen et al43 have showed that detoxiﬁcation of peroxide by
neurons is less efﬁcient than astrocytes, indicating an increase in
Figure 6. NAD+/NADH ratio, and ATP levels inside the cells after
treatment of NT2.N/A with 2 μmol/L amyloid beta (Aβ). (A) NAD+,
NADH, and (B) ATP were measured after 6, 24, 48, 72, and 96 hours.
Results are expressed as ratio± s.e.m. (A) and nmol/mg protein± s.e.
m. (B), n= 3. Po0.05 (*), Po0.01 (**), Po0.001 (***). Comparisons
between treatments were performed using Students T-test.
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the susceptibility of neurons to oxidative stress compared with
astrocytes. As oxidative stress has been associated with AD, NT2.N/A
and NT2.A cultures were investigated for increases in GSH oxidation
in response to oxidative stress after treatment with Aβ1-42.
Pure astrocytic cultures showed a decrease in GSH/GSSG ratio.
After 48 hours, the ratio increased suggesting a recovery from the
initial insult. A similar decrease in the GSH/GSSG ratio was seen in
cocultures at 6 and 24 hours. A study by Abramov et al44 performed
on rat mixed hippocampal neuronal and glial cultures as well as on
pure cortical astrocytes has linked sporadic Ca2+ signals caused by
Aβ to GSH depletion. Such Ca2+ ﬂuctuations were only seen in
astrocytes and were associated with a decrease in GSH in those
cells. Astrocytes in these cultures were found to withstand this
insult and were resistant to cell death, while neurons were found to
die within 24 hours after exposure, highlighting the importance of
cocultures.44 Results described by Dringen et al43 and Abramov
et al44 also suggest that a compromised astrocytic glutathione
system may contribute to a lower defence capacity of the brain
against reactive oxygen species. As hypoglycaemic conditions may
deplete NADPH levels, this may in turn increase cells susceptibility
to oxidative damage due to a limited ability to reduce GSSG to GSH.
As numerous cell types interact during the progression of AD, it
is important that any in vitro model of the disease reﬂects this
arrangement. Data presented here provide evidence for a
detrimental effect of Aβ on carbohydrate metabolism in both
neurons and astrocytes. Replication of results using a well-
established primary cortical culture model system shows the
utility of stem cell-derived neurons and astrocytes for studying
hypometabolism observed in AD. As a purely in vitro system,
human stem cell models can be readily manipulated and
maintained in culture for a period of months without the use of
animals. In our laboratory, the NT2 model can be maintained in
culture for over 6 months thus providing the opportunity to study
the consequences of these changes over extended periods of time
relevant to aspects of the disease progression timeframe in vivo. In
addition, their human origin provides a more realistic in vitro
model as well as informing other human in vitro models such as
patient-derived induced pluripotent stem cells. Future studies will
attempt to investigate the earliest cell-speciﬁc changes that lead
to hypometabolism using this model as well as the effects of
abnormal metabolism on neuronal and astrocytic activity.
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